IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

IO Biotech, Inc.

IO Biotech develops T-win® technology designed to activate and expand T cells to modulate the tumor microenvironment for cancer treatment.

IO Biotech

IO Biotech is a clinical-stage biopharmaceutical company pioneering the first-in-class investigational dual-action immune-modulating cancer vaccine with the goal of becoming the backbone of combination therapy for people with cancer. The Company’s T-win® vaccine platform is directed against the tumor microenvironment (TME) and is designed to stimulate T cells against tumor cells and the most important immune-suppressive cells in the TME. IO Biotech’s most advanced program for IO102-IO103 is currently in Phase 3 development. IO Biotech is headquartered in Copenhagen, Denmark.

IO Biotech has achieved a proven track record of progressing compounds to the clinic, and has two lead immune modulating anti-cancer therapies targeting IDO and PD-L1 in clinical development and several compounds finalizing preclinical phase.

IO Biotech has an experienced management team within immuno-oncology fields and a world-class advisory board.

Novo Holdings

EIR Ventures

HBM Healthcare Investments AG

Sunstone Life Science Ventures

Vivo Capital

Idinvest Partners

Kurma Partners

Serrado Capital

Soleus Capital

Lundbeckfonden Emerge

IO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature Medicine

IO Biotech is pleased to announce that Faical Miyara Ph.D, CBO, will serve on the ‘Exploring Factors that Drive Biotech Deals’ panel at the LSX World Congress USA taking place on September 11-12 in Boston.
 
The LSX World Congress USA brings together leaders from the US biotech, medtech, and healthtech sectors to network, showcase innovations, and explore partnership opportunities. Learn more about the Congress here: [Biotech, Healthtech & Medtech Investment | LSX USA Congress (informaconnect.com)]

To learn more about IO Biotech and our T-win® immune-modulating therapeutic cancer vaccine, please visit our website: www.iobiotech.com.

IO Biotech is pleased to announce that members of its management team will be attending the following investor conferences in September:
 
Morgan Stanley 22nd Annual Global Healthcare Conference, New York
Date: Wednesday, September 4, 2024, fireside chat at 5:35 pm ET
Presenter: Mai-Britt Zocca, PhD, CEO
 
H.C. Wainwright 26th Annual Global Investment Conference, New York
Date: Monday, September 9, 2024, presentation at 10:30 am ET
Presenter: Amy Sullivan, CFO

For further information, including webcast links, please see the full PR, here: https: https://bit.ly/3YVKpXt
  
#IOBiotech #cancer #InvestorConferences

IO Biotech today reported financial results for the second quarter ended June 30, 2024. Read more: https://bit.ly/3AnOcCy
#IOBiotech #cancer #financialresults

Members of the IO Biotech management team will be heading to Barcelona, Spain for ESMO - European Society for Medical Oncology 2024 on September 13th – 17th to connect with fellow oncology professionals. Reach out to us at info@iobiotech.com to meet with our CEO Mai-Britt Zocca, CMO Dr. Qasim Iftikhar Ahmad, or CBO Faical Miyara Ph.D, to learn more about our novel investigational IO102-IO103 therapeutic cancer vaccine.

We hope to see you at our poster presentation at the congress, "A phase 2 trial of the IO102-IO103 vaccine plus pembrolizumab: completed cohort for first line (1L) treatment of advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)", presentation no. 1022P.

Summer is the time of year when people spend more time outdoors and this Summer Sun Safety Month, IO Biotech encourages everyone to stay safe while enjoying the sun. Remember to prioritize skin health and be mindful of the risks of #melanoma, a serious form of #skincancer linked to UV exposure.
 
The "ABCDE" rule is helpful in remembering the warning signs of melanoma:
·       Asymmetry. The shape of one-half of the mole does not match the other
·       Border. The edges are ragged, notched, uneven, or blurred
·       Color. Shades of black, brown, and tan may be present
·       Diameter. Can be smaller than a pencil eraser
·       Evolving. Shape is changing in size, shape, or color
 
To learn more about IO Biotech and our T-win® immune-modulating therapeutic cancer vaccine, please visit our website: www.iobiotech.com.
'#SummerSunSafety #MelanomaAwareness #IOBiotech

IO Biotech is pleased to announce that it will be presenting a poster at the ESMO - European Society for Medical Oncology Congress 2024.

The poster is entitled "A phase 2 trial of the IO102-IO103 vaccine plus pembrolizumab: completed cohort for first line (1L) treatment of advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)" and will share data from one of the Phase 2 basket trials of IO102-IO103 in combination with pembrolizumab (KEYTRUDA®), Merck’s anti-PD-1 therapy. The data for the complete squamous cell carcinoma of the head and neck (SCCHN) cohort of the IOB-022/KN-D38 study will be presented at the Congress, which takes place in Barcelona from September 13-17, 2024. 

We look forward to sharing these exciting data.

See full details here: https://bit.ly/4fiB5m2
#ESMO24 #IOBiotech #cancer #SCCHN

July is UV Safety Month. Most skin cancers are caused by too much exposure to ultraviolet (UV) light. Learn more on how to protect yourself when outdoors year-round with three simple steps from the American Academy of Dermatology Association here: https://bit.ly/4bHv6Em
#PracticeSafeSun

IO Biotech is proud to congratulate Inge-Marie Svane, MD, PhD, one of our co-founders, on receiving the prestigious Kirsten and Freddy Johansen’s Medical Scientific Clinical Researcher Award 2024! We want to thank Dr. Svane for all of her contributions and research efforts to help people with cancer around the world.

IO Biotech is hiring. Learn more here: https://bit.ly/4cvL8lC

NASDAQ:IOBT

IO Biotech

Last Close

1.54

30/08 20:00

Market Cap

82.35M

Beta: -

Volume Today

695.04K

Avg: 33.85K

PE Ratio

−1.16

PFCF: −1.81

locale

market

industry

website

ipo date

peer of

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics